DepoMed, Inc. (NASDAQ:DEPO)

CAPS Rating: 4 out of 5

A specialty pharmaceutical company focused on the development and commercialization of differentiated products that address growing markets and are based on proprietary oral drug delivery technologies.

Recs

1
Player Avatar ssbb123 (28.15) Submitted: 2/22/2010 3:16:36 PM : Underperform Start Price: $2.46 DEPO Score: -474.77

"Cancer risk" can't see this being a good investment for the next few months at least.
http://www.forbes.com/2010/02/18/xenoport-glaxosmithkline-depomed-markets-equities-pharmaceuticals.html?partner=yahootix

Featured Broker Partners


Advertisement